Neuroendocrine Tumor Overview

Save information for later
Sign Up

Learn About Neuroendocrine Tumor

What is the definition of Neuroendocrine Tumor?
Neuroendocrine tumors are rare cancers that grow from neuroendocrine cells. Neuroendocrine cells receive signals from the nervous system to release hormones. There are several types of neuroendocrine tumors, although most occur in the lungs, pancreas, adrenal glands, small intestine, appendix, and rectum. Neuroendocrine tumors may also spread to the lymph nodes, liver, or bones.
What are the symptoms of Neuroendocrine Tumor?
Symptoms of a neuroendocrine tumor depend on the tumor’s location and whether it is producing excess hormones. Symptoms of neuroendocrine tumors may include pain, a lump under the skin, fatigue, persistent cough or hoarseness, unexplained weight loss, confusion, anxiety, dizziness, shakiness, elevated blood glucose, low blood glucose, an ulcer, skin flushing, skin rash, increased thirst, nausea and vomiting, diarrhea, and carcinoid syndrome. Carcinoid syndrome is a condition that occurs when a neuroendocrine tumor produces excess hormones. Symptoms of carcinoid syndrome include skin flushing of the head and neck; sweating; shortness of breath; wheezing; rapid heartbeat; heart murmur; high blood pressure; yellowing of the skin and eyes; abdominal cramping; diarrhea; greasy, foul-smelling bowel movements; and swelling of the feet and legs.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Neuroendocrine Tumor?
Treatment for neuroendocrine tumors depends on the type and location, as well as whether the tumor is producing excess hormones. Treatment for endocrine tumors may include surgery; chemotherapy; targeted drug therapy, such as everolimus and sunitinib; immunotherapy, such as interferon alfa-2b; peptide receptor radionuclide therapy; somatostatin analogs, such as octreotide and lanreotide; radiation therapy; radiofrequency ablation; and hepatic artery embolization.
Who are the top Neuroendocrine Tumor Local Doctors?
James C. Yao
Elite in Neuroendocrine Tumor
Dr. James C. Yao
Oncology
Elite in Neuroendocrine Tumor
Dr. James C. Yao
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances

James Yao is an Oncologist in Houston, Texas. Dr. Yao is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Metastatic Insulinoma, Carcinoid Syndrome, and Pancreatectomy.

Elite in Neuroendocrine Tumor
Dr. Matthew H. Kulke
Oncology
Elite in Neuroendocrine Tumor
Dr. Matthew H. Kulke
Oncology

Evans Medical Foundation Inc

88 E Newton St, 
Boston, MA 
617-414-5405
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Kulke is an Oncologist in Boston, Massachusetts. Dr. Kulke is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Carcinoid Syndrome, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Liver Embolization. Dr. Kulke is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Neuroendocrine Tumor
Dr. Daneng G. Li
Oncology
Elite in Neuroendocrine Tumor
Dr. Daneng G. Li
Oncology

City Of Hope Medical Foundation

1500 E Duarte Rd, 
Duarte, CA 
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daneng Li is an Oncologist in Duarte, California. Dr. Li has been practicing medicine for over 16 years and is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Lymphadenectomy, and Colonoscopy.

View All Doctors
What are the latest Neuroendocrine Tumor Clinical Trials?
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint Inhibitor Naïve Subjects With Advanced Or Metastatic Merkel Cell Carcinoma
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint Inhibitor Naïve Subjects With Advanced Or Metastatic Merkel Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion followed by pembrolizumab.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Who is this study for: Patients with Metastatic Cutaneous Melanoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3

Summary: This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with mon...

View All Clinical Trials